The U.S. Food and Drug Administration (FDA) has granted an expanded indication for Vonvendi, Takeda’s recombinant von Willebrand factor (rVWF) therapy, marking a significant advancement in the management of rare…
Von Willebrand disease, or VWD, affects about 1% of the American population, but until recently, there was no dedicated therapy to treat it. If you're unfamiliar with this rare disease, VWD…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
